Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)
Close on Nov 17, 2026Market cap $476.21MP/E –Yield –
Fennec Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Fennec Pharmaceuticals's total assets was $75.75M at Jun 30, 2026. For fiscal 2025 it was $70.55M, up 57.0% from the year before. Over ten years it grew 52.8% a year on average. The highest annual figure on record is $70.55M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.55M | +57.0% |
| FY2024 | Dec 31, 2024 | $44.95M | +67.3% |
| FY2023 | Dec 31, 2023 | $26.86M | -0.3% |
| FY2022 | Dec 31, 2022 | $26.94M | +20.2% |
| FY2021 | Dec 31, 2021 | $22.41M | -28.7% |
| FY2020 | Dec 31, 2020 | $31.42M | +122.1% |
| FY2019 | Dec 31, 2019 | $14.15M | -38.4% |
| FY2018 | Dec 31, 2018 | $22.95M | -19.2% |
| FY2017 | Dec 31, 2017 | $28.40M | +615.0% |
| FY2016 | Dec 31, 2016 | $3.97M | +289.8% |
| FY2015 | Dec 31, 2015 | $1.02M | -57.0% |
| FY2014 | Dec 31, 2014 | $2.37M | +35.4% |
| FY2013 | Dec 31, 2013 | $1.75M | -25.9% |
| FY2012 | Dec 31, 2012 | $2.37M | -55.8% |
| FY2011 | Dec 31, 2011 | $5.35M | -10.7% |
| FY2010 | Dec 31, 2010 | $5.99M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $75.75M | +68.8% |
| Q1 FY2026 | Mar 31, 2026 | $71.82M | +54.8% |
| Q4 FY2025 | Dec 31, 2025 | $70.55M | +57.0% |
| Q3 FY2025 | Sep 30, 2025 | $49.26M | -16.4% |
| Q2 FY2025 | Jun 30, 2025 | $44.88M | -28.9% |
| Q1 FY2025 | Mar 31, 2025 | $46.40M | -32.9% |
| Q4 FY2024 | Dec 31, 2024 | $44.95M | +67.3% |
| Q3 FY2024 | Sep 30, 2024 | $58.92M | +194.9% |
| Q2 FY2024 | Jun 30, 2024 | $63.16M | +225.0% |
| Q1 FY2024 | Mar 31, 2024 | $69.19M | +217.1% |
| Q4 FY2023 | Dec 31, 2023 | $26.86M | -0.3% |
| Q3 FY2023 | Sep 30, 2023 | $19.98M | -34.3% |
| Q2 FY2023 | Jun 30, 2023 | $19.44M | +24.9% |
| Q1 FY2023 | Mar 31, 2023 | $21.82M | +14.0% |
| Q4 FY2022 | Dec 31, 2022 | $26.94M | +20.2% |
| Q3 FY2022 | Sep 30, 2022 | $30.42M | +16.9% |
| Q2 FY2022 | Jun 30, 2022 | $15.57M | -44.6% |
| Q1 FY2022 | Mar 31, 2022 | $19.15M | -31.2% |
| Q4 FY2021 | Dec 31, 2021 | $22.41M | -28.7% |
| Q3 FY2021 | Sep 30, 2021 | $26.01M | -23.6% |
| Q2 FY2021 | Jun 30, 2021 | $28.12M | -28.5% |
| Q1 FY2021 | Mar 31, 2021 | $27.83M | +168.4% |
| Q4 FY2020 | Dec 31, 2020 | $31.42M | +122.1% |
| Q3 FY2020 | Sep 30, 2020 | $34.07M | +114.2% |
| Q2 FY2020 | Jun 30, 2020 | $39.32M | +120.5% |
| Q1 FY2020 | Mar 31, 2020 | $10.37M | -49.8% |
| Q4 FY2019 | Dec 31, 2019 | $14.15M | -38.4% |
| Q3 FY2019 | Sep 30, 2019 | $15.91M | -38.1% |
| Q2 FY2019 | Jun 30, 2019 | $17.83M | -33.6% |
| Q1 FY2019 | Mar 31, 2019 | $20.66M | -27.3% |
| Q4 FY2018 | Dec 31, 2018 | $22.95M | +132.1% |
| Q2 FY2018 | Jun 30, 2018 | $25.70M | +150.6% |
| Q1 FY2018 | Mar 31, 2018 | $26.84M | +716.2% |
| Q4 FY2017 | Dec 31, 2017 | $28.40M | +615.0% |
| Q3 FY2017 | Sep 30, 2017 | $9.89M | +115.9% |
| Q2 FY2017 | Jun 30, 2017 | $10.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.97M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.58M | – |
See a number that looks wrong?